Bristol-Myers Squibb Co. said U.S. regulators are satisfied with the corrective actions the drug maker took to resolve deficiencies at a Puerto Rico manufacturing plant that drew a warning letter last year. The resolution could clear the way for regulatory approval of two Bristol drugs that had been on hold because they will be manufactured at the Manati, Puerto Rico, plant.
